The DOI matches its Crossref record.
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
Open accessAbstract
Drug delivery and penetration into neoplastic cells distant from tumor vessels are critical for the effectiveness of solid-tumor chemotherapy.We have found that targeted delivery to tumor vessels of picogram doses of TNF-α (TNF), a cytokine able to alter endothelial barrier function and tumor interstitial pressure, enhances the penetration of doxorubicin in tumors in murine models.Vascular targeting was achieved by coupling TNF with CNGRC, a peptide that targets the tumor neovasculature.This treatment enhanced eight-to tenfold the therapeutic efficacy of doxorubicin, with no evidence of increased toxicity.Similarly, vascular targeting enhanced the efficacy of melphalan, a different chemotherapeutic drug.Synergy with chemotherapy was observed with 3-5 ng/kg of targeted TNF (intraperitoneally), about 10 6 -fold lower than the LD 50 and 10 5 -fold lower than the dose required for nontargeted TNF.In addition, we have also found that targeted delivery of low doses of TNF to tumor vessels does not induce the release of soluble TNF receptors into the circulation.The delivery of minute amounts of TNF to tumor vessels represents a new approach for avoiding negative feedback mechanisms and preserving its ability to alter drug-penetration barriers.Vascular targeting could be a novel strategy for increasing the therapeutic index of chemotherapeutic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 26
- Jain, 1994, Sci Am, 271, 58, 10.1038/scientificamerican0794-58 · DOI · Paper page
- Lienard, 1992, J Clin Oncol, 10, 52, 10.1200/JCO.1992.10.1.52 · DOI · Paper page
- Eggermont, 1996, J Clin Oncol, 14, 2653, 10.1200/JCO.1996.14.10.2653 · DOI · Paper page
- Lejeune, 1995, Eur J Cancer, 31A, 1009, 10.1016/0959-8049(94)00512-5 · DOI
- Fraker, 1996, J Clin Oncol, 14, 479, 10.1200/JCO.1996.14.2.479 · DOI · Paper page
- 10.1002/(SICI)1097-0142(19991101)86:9<1742::AID-CNCR16>3.0.CO;2-G · doi:10.1002/(sici)1097-0142(19991101)86:9<1742::aid-cncr16>3.0.co;2-g
- 10.1054/bjoc.1999.1027 · DOI
- Kristensen, 1996, Br J Cancer, 74, 533, 10.1038/bjc.1996.397 · DOI
- 10.1002/ijc.2910460624 · doi:10.1002/ijc.2910460624
- 10.1054/bjoc.1999.1032 · DOI · Paper page
- Corti, 1998, J Drug Target, 5, 403, 10.3109/10611869808997869 · doi:10.3109/10611869808997869
- 10.1038/81183 · DOI · Paper page
- Moro, 1997, Cancer Res, 57, 1922
- Corti, 1999, Infect Immun, 67, 5762, 10.1128/IAI.67.11.5762-5767.1999 · DOI
- Pelagi, 2000, Eur Cytokine Netw, 11, 580
- 10.1016/0022-1759(94)90156-2 · doi:10.1016/0022-1759(94)90156-2
- Smith, 1987, J Biol Chem, 262, 6951, 10.1016/S0021-9258(18)48183-5 · DOI · Paper page
- Gasparri, 1999, Cancer Res, 59, 2917
- 10.1172/JCI694 · DOI
- 10.1073/pnas.88.20.9292 · DOI · Paper page
- 10.1093/jnci/81.1.55 · DOI
- Sella, 1995, Cancer Biother, 10, 225, 10.1089/cbr.1995.10.225 · doi:10.1089/cbr.1995.10.225
- 10.1084/jem.169.6.1977 · DOI · Paper page
- Goldblum, 1990, Am J Physiol, 258, L57
- Curnis, 2002, Cancer Res, 62, 867
- 10.1126/science.279.5349.377 · DOI · Paper page
Cited by
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
“An increased uptake of doxorubicin after delivery of TNFα to tumour vessels has been demonstrate”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Tumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 701
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Paciotti, G. F., Kingston, D. G. I., & Tamarkin, L. (2006) · Drug Development Research · doi:10.1002/ddr.20066 · Cited by 484
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis
Emerich, D. F., & Thanos, C. G. (2006) · Biomolecular Engineering · doi:10.1016/j.bioeng.2006.05.026 · Cited by 312
The tumor microenvironment and metastatic disease
Lunt, S. J., Chaudary, N., & Hill, R. P. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9182-2 · Cited by 298
From Combinatorial Chemistry to Cancer-Targeting Peptides
Aina, O. H., Liu, R., Sutcliffe, J. L., Marik, J., Pan, C.-X., & Lam, K. S. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700073y · Cited by 285
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
Development and characterization of a microfluidic model of the tumour microenvironment
Ayuso, J. M., Virumbrales-Muñoz, M., Lacueva, A., Lanuza, P. M., Checa-Chavarria, E., Botella, P., Fernández, E., Doblare, M., Allison, S. J., Phillips, R. M., et al. (2016) · Scientific Reports · doi:10.1038/srep36086 · Cited by 134
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Zhang, B., Jiang, T., Tuo, Y., Jin, K., Luo, Z., Shi, W., Mei, H., Hu, Y., Pang, Z., & Jiang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.007 · Cited by 41
Gasparri, A. M., Sacchi, A., Basso, V., Cortesi, F., Freschi, M., Rrapaj, E., Bellone, M., Casorati, G., Dellabona, P., Mondino, A., et al. (2019) · Small · doi:10.1002/smll.201903462 · Cited by 37
Self-citation
Metadata
- Authors
- Curnis, F., Sacchi, A., & Corti, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-15
- Volume
- 110
- Issue
- 4
- Pages
- 475-482
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4240420638
- Cited by
- 228
- References
- 0
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.